The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | R | Respiratory system | |
| 2 | R05 | Cough and cold preparations | |
| 3 | R05D | Cough suppressants, excl. combinations with expectorants | |
| 4 | R05DB | Other cough suppressants | |
| 5 | R05DB29 |
| Active Ingredient | Description | |
|---|---|---|
| Gefapixant |
Gefapixant is a selective antagonist of the P2X3 receptor. P2X3 receptors are ATP-gated ion channels found on sensory C fibres of the vagus nerve in the airways. C fibres are activated in response to inflammation or chemical irritants. Blockade of ATP signalling through P2X3 receptors reduces excessive sensory-nerve activation and excessive cough induced by extracellular ATP. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| LYFNUA Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
